Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Nagaland State Lottery Result: February 18, 2026, 1 PM Live - Watch Streaming Of Winners List Of Dear Indus Sambad Morning Wednesday Weekly Draw
'Was Inappropriate...': Neena Gupta Recalls Subhash Ghai Asked Her To Wear Padded Bra For Choli Ke Peeche To 'Appear Fuller'
SBI Mains Result 2026 Likely Soon: Here’s How To Access Results
'Toxic Is A Savage Action-Thriller Saga That Plunges...': Storyline Of Yash Starrer Leaked
